Article Text

other Versions

PDF
Direct oral anticoagulants: unique properties and practical approaches to management
  1. Geoffrey D Barnes1,
  2. Brian Kurtz2
  1. 1Frankel Cardiovascular Center and Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA
  2. 2Frankel Cardiovascular Center Outpatient Anticoagulation Service, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to Dr Geoffrey Barnes, Internal Medicine, University of Michigan, 2800 Plymouth Rd—B14 G101, Ann Arbor, MI 48109, USA; gbarnes{at}umich.edu

Abstract

Since 2009, four direct oral anticoagulants (DOACs) have been introduced for treatment of venous thromboembolism and stroke prevention in non-valvular atrial fibrillation. While they are currently first-line therapy for a majority of patients, there are a number of clinical situations where warfarin is preferable. In both randomised trials and real-world populations, use of DOACs significantly reduces the risk of intracranial haemorrhage as compared with warfarin. While drug-specific reversal agents are currently only available for dabigatran, andexanet alpha is pending approval for reversal of factor Xa inhibitors, reducing concerns about major bleeding for many patients and providers. DOACs can be held for 2–4 days prior to a procedure, depending on a patient’s renal function, but should not be restarted too rapidly post-procedurally given their fast time to peak activity (∼2 hours). The anticoagulation clinic should play an important role in managing patients on all oral anticoagulation, both warfarin and DOACs.

View Full Text

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.